Danish Infrastructure Stock News

Novo Nordisk’s experimental sickle cell disease drug etavopivat met both co primary endpoints in a phase 3 trial. The data indicate significant efficacy in sickle cell disease, an area with substantial unmet medical need. The company plans to seek its first regulatory approval for etavopivat in the second half of 2026. Novo Nordisk, traded as CPSE:NOVO B, is best known for its diabetes and obesity treatments. Etavopivat points to a broader rare disease focus. The share price stands at...

Wondering whether A.P. Møller - Mærsk is priced attractively right now, or if the recent run leaves less room for value focused investors. The share price closed at DKK 14,990, with a 1 year return of 43.3% and a 5 year return of 87.0%, while shorter term moves include a 7 day return of 5.9% decline and a 30 day return of 13.0% decline, with a 2.0% gain year to date. Recent share price moves sit against a backdrop of ongoing interest in global shipping and logistics, where investors continue...

Ringkjøbing Landbobank (CPSE:RILBA) has drawn fresh attention after a strong 1 year total return of 40.2%, prompting investors to reassess the Danish lender’s performance metrics and current valuation. See our latest analysis for Ringkjøbing Landbobank. Recent trading has been relatively constructive, with a 30 day share price return of 8.94% and a 1 year total shareholder return of 40.23%. This suggests momentum has been building over time rather than fading. If you are comparing Ringkjøbing...

As European markets experience a positive shift, with the STOXX Europe 600 Index rising by 1.91%, investors are keenly observing corporate earnings and geopolitical developments. Amid these broader market dynamics, penny stocks continue to capture interest for their potential to unlock growth opportunities in smaller or emerging companies. Though the term 'penny stock' may seem outdated, it remains pertinent as these investments can offer significant returns when backed by solid financial...

Hove A/S ( CPH:HOVE ) stock is about to trade ex-dividend in three days. The ex-dividend date is usually set to be two...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

DFDS (CPSE:DFDS) has raised its 2026 EBIT outlook to DKK 1,000 million to DKK 1,400 million after five of six key initiatives, led by the Mediterranean ferry network, performed ahead of expectations. See our latest analysis for DFDS. The raised 2026 EBIT outlook appears to have coincided with strong momentum in the shares, with a 30 day share price return of 53.91% and a 1 year total shareholder return of 77.57%, even though the 3 and 5 year total shareholder returns remain negative. If...

We'd be surprised if SKAKO A/S ( CPH:SKAKO ) shareholders haven't noticed that the MD, CEO & Non-Independent Director...

Recent performance snapshot for A.P. Møller - Mærsk (CPSE:MAERSK B) A.P. Møller - Mærsk (CPSE:MAERSK B) has seen mixed share price returns, with a 1 day move of a 2.83% decline, a 7 day decline of 3.44%, a month decline of 11.27%, and a past 3 months gain of 3.98%. See our latest analysis for A.P. Møller - Mærsk. The recent 11.27% 1 month share price decline contrasts with a 4.02% year to date share price gain and a 46.06% 1 year total shareholder return, suggesting shorter term momentum has...

ALK-Abelló recently reported that Health Canada has approved neffy 2 mg, the first nasal adrenaline spray for emergency treatment of anaphylaxis in adults and paediatric patients weighing at least 30 kg, with a Canadian launch planned in the coming months. This approval opens a new market for ALK-Abelló outside Europe and highlights neffy’s portability, long shelf life and high-temperature resilience versus traditional auto-injectors. We’ll now examine how gaining Canadian approval for...

Danske Bank has confirmed that more than 20,000 customer addresses were accidentally exposed to third parties. The bank has acknowledged the incident, initiated reconciliation reviews, and strengthened internal controls in response. The exposure affects a significant number of customers and raises questions around data privacy and operational processes. For you as an investor looking at CPSE:DANSKE, this incident comes at a time when the bank’s shares are trading at DKK333.8 and its value...

It looks like Danske Andelskassers Bank A/S ( CPH:DAB ) is about to go ex-dividend in the next 3 days. The ex-dividend...

Carlsberg stock at a glance Carlsberg (CPSE:CARL B) has drawn attention after a recent move in its share price, with the stock up 2.6% over the past day but showing mixed returns over the month and past 3 months. See our latest analysis for Carlsberg. The recent 2.6% daily share price gain to DKK846.4 comes against a year to date share price return of 2.5% and a 1 year total shareholder return of a 2.4% decline. This suggests momentum has been muted despite earlier growth and profit...

Genmab (CPSE:GMAB) has reported new clinical data for its antibody drug conjugate rinatabart sesutecan, known as Rina S, in advanced ovarian cancer. The therapy, in combination with bevacizumab, showed a tolerable safety profile with no new or unexpected safety signals in patients. The results were presented at a major oncology conference, adding fresh information on Genmab’s oncology pipeline. For investors tracking Genmab, the update on Rina S comes with the share price at DKK1,804.0 and...

Swiss Properties Invest A/S' ( CPH:SWISS ) stock wasn't much affected by its recent lackluster earnings numbers. We did...

Wondering whether Pandora, at a last close of kr.514.2, now reflects fair value or if the market is mispricing the story? This article focuses squarely on what that price actually implies. The share price has moved sharply in the short term, with returns of 8.8% over 7 days and 18.3% over 30 days, against a year-to-date return of 26.1% and a 1-year return of 41.4%. Recent coverage of Pandora has centered on how these sharp moves fit into the longer track record of returns over 3 and 5 years,...

Recent performance snapshot Tryg (CPSE:TRYG) has drawn interest after a mixed run in its shares, with a 0.8% decline over the past day, a 2.2% gain over the week, and a modest move higher over the month. Over the past 3 months the stock shows a 2.1% decline, while the 1 year total return stands at 10.0%, giving investors a reference point for how recent trading compares with its longer record. See our latest analysis for Tryg. With the share price at DKK158.3, the recent 7 day share price...

Wondering if Carlsberg at DKK 825.20 is offering fair value or a potential mismatch between price and fundamentals? This article focuses squarely on what that current price could mean for you. The share price has seen recent weakness, with returns of a 2.7% decline over 7 days, 4.8% decline over 30 days, 0.1% decline year to date, 4.8% decline over 1 year, 17.5% decline over 3 years and 11.7% decline over 5 years. This naturally raises questions about whether risk is being reassessed or if...

Wondering whether Novo Nordisk at around DKK 262.20 is offering value or just noise in a volatile market? This article breaks down what the price tag might really be telling you. The stock has moved 10.1% over the past week and 5.2% over the past month, while the year-to-date return stands at a 20.6% decline and the 1-year return at a 34.9% decline, which may catch the eye of investors weighing potential opportunity against risk. Recent coverage has focused on how sentiment toward large...

Vestas Wind Systems (CPSE:VWS) is back in focus after securing a 70 MW order for the Strazhitsa wind project in Bulgaria, paired with a long term service deal and fresh governance updates. See our latest analysis for Vestas Wind Systems. The recent 70 MW Bulgarian order, dividend approval and board changes arrive as Vestas posts a 27.0% 1 month share price return and a very large 1 year total shareholder return. However, the 5 year total shareholder return of a 15.57% decline shows that...

Q1 2026 earnings snapshot and how the story might be shifting Tryg (CPSE:TRYG) has set the stage for its Q1 2026 update with Q4 2025 revenue of about DKK 10.9 billion and Basic EPS of DKK 2.06, underpinned by trailing twelve month revenue of roughly DKK 43.0 billion and EPS of DKK 8.83. Over recent quarters, the company has seen revenue move from DKK 9.94 billion in Q4 2024 to around DKK 10.9 billion in Q4 2025, while quarterly EPS shifted from DKK 1.22 to DKK 2.06. This gives investors a...

If you are wondering whether Genmab shares are offering fair value at current levels or if the price is getting ahead of itself, this article breaks down what the numbers say about the stock. Over the past week Genmab is up 2.9%. Over the last month it is up 7.3%. Year to date the return sits at an 8.3% decline, while the 1 year return is 42.5%. Taken together, this gives a mixed picture for anyone eyeing the recent share price. These moves sit against a backdrop where investors are weighing...

Novo Nordisk recently announced a wide-ranging partnership with OpenAI to integrate advanced AI across drug discovery, manufacturing, supply chain and commercial operations, with pilot projects underway and full roll-out targeted by the end of 2026 under strict data governance and human oversight. This collaboration could reshape how Novo Nordisk develops and delivers treatments by using AI to interpret complex datasets, shorten research timelines and support more efficient global operations...

Alm. Brand (CPSE:ALMB) has drawn attention after extending its collaboration with Ondo InsurTech’s LeakBot. The insurer plans to offer the leak detection device to up to 160,000 homeowners across its Danish insurance brands. See our latest analysis for Alm. Brand. The expanded LeakBot rollout and recent AGM decisions come after a weaker short term patch, with a 90 day share price return of 16.44% decline and year to date share price return of 17.74% decline, set against a 1 year total...